Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors
Human endogenous retroviruses (HERVs), remnants of ancient germ-line infections with exogenous retroviruses, are estimated to comprise up to 8% of human genome. Most HERVs have accumulated mutations and deletions that prevent their expression as an infectious virus. Nevertheless, a growing number of...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2013-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00243/full |
id |
doaj-79b22e60ae1f44169563225234eae75a |
---|---|
record_format |
Article |
spelling |
doaj-79b22e60ae1f44169563225234eae75a2020-11-25T01:01:06ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2013-09-01310.3389/fonc.2013.0024361020Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumorsElena eCherkasova0Quinn eWeisman1Richard W. Childs2National Institute of HealthNational Institute of HealthNational Institute of HealthHuman endogenous retroviruses (HERVs), remnants of ancient germ-line infections with exogenous retroviruses, are estimated to comprise up to 8% of human genome. Most HERVs have accumulated mutations and deletions that prevent their expression as an infectious virus. Nevertheless, a growing number of HERV genes and proteins have been found to be expressed in different cancers, raising the possibility that HERV-derived antigens might represent excellent targets for tumor immunotherapy. Here, we review data showing HERV-encoded antigens are capable of eliciting humoral and T cells specific antitumor immunity. We also describe a novel HERV-E that was recently found to be selectively expressed in over 80% of clear cell kidney cancer but not in normal tissues. Remarkably, the restricted expression of HERV-E in kidney tumors was found to occur as a consequence of inactivation of the VHL tumor suppressor. Importantly, antigens derived from this provirus are immunogenic, stimulating cytotoxic T cells that kill kidney cancer cells in vitro and in vivo. Taken altogether, these data suggest efforts aimed at boosting human immunity against HERV-derived antigens could be used as a strategy to treat advanced tumors including kidney cancer.http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00243/fullImmunotherapycancer treatmentantigenCytotoxic T Cellshuman endogenous retroviruses |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elena eCherkasova Quinn eWeisman Richard W. Childs |
spellingShingle |
Elena eCherkasova Quinn eWeisman Richard W. Childs Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors Frontiers in Oncology Immunotherapy cancer treatment antigen Cytotoxic T Cells human endogenous retroviruses |
author_facet |
Elena eCherkasova Quinn eWeisman Richard W. Childs |
author_sort |
Elena eCherkasova |
title |
Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors |
title_short |
Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors |
title_full |
Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors |
title_fullStr |
Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors |
title_full_unstemmed |
Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors |
title_sort |
endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2013-09-01 |
description |
Human endogenous retroviruses (HERVs), remnants of ancient germ-line infections with exogenous retroviruses, are estimated to comprise up to 8% of human genome. Most HERVs have accumulated mutations and deletions that prevent their expression as an infectious virus. Nevertheless, a growing number of HERV genes and proteins have been found to be expressed in different cancers, raising the possibility that HERV-derived antigens might represent excellent targets for tumor immunotherapy. Here, we review data showing HERV-encoded antigens are capable of eliciting humoral and T cells specific antitumor immunity. We also describe a novel HERV-E that was recently found to be selectively expressed in over 80% of clear cell kidney cancer but not in normal tissues. Remarkably, the restricted expression of HERV-E in kidney tumors was found to occur as a consequence of inactivation of the VHL tumor suppressor. Importantly, antigens derived from this provirus are immunogenic, stimulating cytotoxic T cells that kill kidney cancer cells in vitro and in vivo. Taken altogether, these data suggest efforts aimed at boosting human immunity against HERV-derived antigens could be used as a strategy to treat advanced tumors including kidney cancer. |
topic |
Immunotherapy cancer treatment antigen Cytotoxic T Cells human endogenous retroviruses |
url |
http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00243/full |
work_keys_str_mv |
AT elenaecherkasova endogenousretrovirusesastargetsforantitumorimmunityinrenalcellcancerandothertumors AT quinneweisman endogenousretrovirusesastargetsforantitumorimmunityinrenalcellcancerandothertumors AT richardwchilds endogenousretrovirusesastargetsforantitumorimmunityinrenalcellcancerandothertumors |
_version_ |
1725210838072033280 |